Hyperthermic Intraperitoneal Chemotherapy for Recurrent Nephroblastoma in Children
Jia-Rong Wang1, de-Guang Meng1, Ya-Nan Hu1
1Department of Oncology, Baoding Children's Hospital, Baoding, China.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|February 16, 2023
Summary
Hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves treatment effectiveness and reduces recurrence rates in children with recurrent nephroblastoma. This approach is safe, with no increased adverse reactions or significant impact on bodily functions.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
Background:
- Recurrent nephroblastoma in children presents a significant clinical challenge.
- Hyperthermic intraperitoneal chemotherapy (HIPEC) is an evolving treatment modality.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of HIPEC for pediatric recurrent nephroblastoma.
- To compare HIPEC outcomes with standard treatment in a control group.
Main Methods:
- A randomized controlled trial involving 90 children with recurrent nephroblastoma.
- Patients were divided into two HIPEC groups (A and B) with different drugs and one control group (C).
- Clinical efficacy, adverse reactions, and tumor recurrence rates at 6 and 12 months were assessed.
Main Results:
- HIPEC groups (A and B) demonstrated significantly higher efficacy compared to the control group (C).
- No significant differences in routine blood indices, albumin, or hepatic/renal function were observed among groups post-treatment.
- While 6-month recurrence rates were similar, 12-month recurrence was significantly lower in HIPEC groups compared to the control group.
Conclusions:
- Intraoperative HIPEC is effective in improving outcomes for children with recurrent nephroblastoma.
- HIPEC significantly reduces tumor recurrence rates at 12 months without increasing adverse events.
- The procedure shows minimal impact on overall bodily functions, highlighting its safety profile.
